dehydrated alcohol
DEHYDRATED ALCOHOL (dehydrated alcohol) is intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin. First approved in 2025.
Drug data last refreshed Yesterday
Dehydrated Alcohol is an intravenous solution approved in October 2025 for hypertension management. It works by intra-arterial catheter delivery into a target septal vessel, causing the hypertrophied septum to thin and reducing blood pressure. This represents a novel interventional approach to treatment-resistant hypertension.
Early-stage launch in October 2025 will require rapid commercial infrastructure build with small, specialized teams focused on interventional cardiologist engagement.
intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Dehydrated Alcohol offers a rare opportunity to build a specialty interventional hypertension franchise from launch, though the single linked job posting suggests a highly specialized, limited-scale commercial operation. This is ideal for candidates seeking deep technical expertise in a niche market rather than large-scale commercial scale.
1 open roles linked to this drug
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.